During the past decade, LG Life Sciences conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "LG Life Sciences" are "Type 2 Diabetes Mellitus" (3 trials) and "Healthy" (1 trials). Many other conditions were trialed in "LG Life Sciences" in a lesser frequency.

Most popular intervention types in "LG Life Sciences" are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "LC15-0444 50mg qd" (2 trials), "Gemigliptin 50mg" (1 trials), "LC15-0444 25mg bid" (1 trials), "Metformin" (1 trials) and "Placebo group(once daily)" (1 trials). Other intervention names were less common.

The vast majority of trials in "LG Life Sciences" are 3 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "LG Life Sciences". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in LG Life Sciences, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in LG Life Sciences, 1 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".